Valsartan - Novartis
Alternative Names: CGP-48933; Diovan; Diovane; Kalpress; Miten; Nisis; Provas; Tareg; Valpression; Vals; VarexanLatest Information Update: 05 Nov 2023
At a glance
- Originator Novartis
- Developer ESTEVE; JW Pharmaceutical; Novartis; Zeneca Farma
- Class Antihypertensives; Branched-chain amino acids; Cardiovascular therapies; Small molecules; Tetrazoles
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Essential hypertension; Heart failure; Hypertension; Postmyocardial infarction
- Discontinued Kidney disorders; Pulmonary fibrosis; Type 2 diabetes mellitus
Most Recent Events
- 01 Feb 2023 Discontinued - Phase-III for Hypertension (In children) in Belgium, France, Germany, Hungary, Italy, Lithuania, Poland, Spain, Guatemala, Brazil (PO)
- 06 Jan 2020 No development reported - Phase-III for Hypertension (In children) in Spain, Poland, Lithuania, Italy, Hungary, Germany, France, Belgium, Brazil, Guatemala (PO)
- 31 Aug 2019 Efficacy and adverse events data from a phase III trial in Hypertension, with or without chronic kidney disease presented at the Annual Congress of the European Society of Cardiology (ESC-2019)